Trials / Completed
CompletedNCT02164500
JAK-inhibition in Recurrent Classical Hodgkin Lymphoma
A Phase II, Open-label, Prospective, Non-randomized, Multicenter Clinical Trial With the JAK-inhibitor Ruxolitinib in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- University of Cologne · Academic / Other
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
The Purpose of this trial is: * to determine the overall response rate (ORR, complete response \[CR\] + partial response \[PR\]) in patients with relapsed or refractory HL * to determine the safety profile of ruxolitinib in patients with relapsed or refractory HL
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ruxolitinib |
Timeline
- Start date
- 2015-10-01
- Primary completion
- 2019-05-17
- Completion
- 2019-05-17
- First posted
- 2014-06-16
- Last updated
- 2020-04-06
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT02164500. Inclusion in this directory is not an endorsement.